Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo

Yosuke Okamura, Ippei Maekawa, Yuji Teramura, Hitomi Maruyama, Makoto Handa, Yasuo Ikeda, Shinji Takeoka

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We studied prototypes of platelet substitutes that bear on their surface a dodecapeptide, HHLG-GAKQAGDV (H12). The peptide is a fibrinogen γ chain carboxy-terminal sequence (γ400-411) and recognizes specifically the active form of glycoprotein (GP) IIb/IIIa on the surface of activated platelets. We conjugated H12 to the end of poly(ethylene glycol) chains on the surface of a phospholipid vesicle with an average diameter of 220 nm to prepare H12-PEG-vesicles. The half-life of the H12-PEG-vesicles was significantly prolonged by PEG modification, and the ability of H12 on the surface of the vesicle to recognize GPIIb/IIIa was maintained even though the surface was modified with PEG chains. The H12-PEG-veiscles enhanced the in vitro thrombus formation of platelets that were adhering to a collagen-immobilized plate, when thrombocytopenia-imitation blood was passed over the plate. Based on the flow cytometric analyses of PAC-1 binding and P-selectin expression, the H12-PEG-vesicles were shown not to cause platelet activation. Furthermore, the H12-PEG-vesicles dose-dependently shortened the tail bleeding time of thrombocytopenic rats. It was confirmed that the H12-PEG-vesicles had a hemostatic effect and may be a suitable candidate for an alternative to human platelet concentrates transfused into thrombocytopenic patients.

Original languageEnglish
Pages (from-to)1589-1596
Number of pages8
JournalBioconjugate Chemistry
Volume16
Issue number6
DOIs
Publication statusPublished - 2005 Nov

Fingerprint

Phospholipids
Hemostatics
Fibrinogen
Polyethylene glycols
Blood Platelets
Platelets
Platelet Glycoprotein GPIIb-IIIa Complex
Bleeding Time
P-Selectin
Ethylene Glycol
Platelet Activation
Thrombocytopenia
Half-Life
Tail
Thrombosis
Collagen
Peptides
In Vitro Techniques
Glycoproteins
Rats

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Okamura, Y., Maekawa, I., Teramura, Y., Maruyama, H., Handa, M., Ikeda, Y., & Takeoka, S. (2005). Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo. Bioconjugate Chemistry, 16(6), 1589-1596. https://doi.org/10.1021/bc050178g

Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo. / Okamura, Yosuke; Maekawa, Ippei; Teramura, Yuji; Maruyama, Hitomi; Handa, Makoto; Ikeda, Yasuo; Takeoka, Shinji.

In: Bioconjugate Chemistry, Vol. 16, No. 6, 11.2005, p. 1589-1596.

Research output: Contribution to journalArticle

Okamura, Y, Maekawa, I, Teramura, Y, Maruyama, H, Handa, M, Ikeda, Y & Takeoka, S 2005, 'Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo', Bioconjugate Chemistry, vol. 16, no. 6, pp. 1589-1596. https://doi.org/10.1021/bc050178g
Okamura, Yosuke ; Maekawa, Ippei ; Teramura, Yuji ; Maruyama, Hitomi ; Handa, Makoto ; Ikeda, Yasuo ; Takeoka, Shinji. / Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo. In: Bioconjugate Chemistry. 2005 ; Vol. 16, No. 6. pp. 1589-1596.
@article{c86de8f7576045f280533c9cbe0e13ea,
title = "Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo",
abstract = "We studied prototypes of platelet substitutes that bear on their surface a dodecapeptide, HHLG-GAKQAGDV (H12). The peptide is a fibrinogen γ chain carboxy-terminal sequence (γ400-411) and recognizes specifically the active form of glycoprotein (GP) IIb/IIIa on the surface of activated platelets. We conjugated H12 to the end of poly(ethylene glycol) chains on the surface of a phospholipid vesicle with an average diameter of 220 nm to prepare H12-PEG-vesicles. The half-life of the H12-PEG-vesicles was significantly prolonged by PEG modification, and the ability of H12 on the surface of the vesicle to recognize GPIIb/IIIa was maintained even though the surface was modified with PEG chains. The H12-PEG-veiscles enhanced the in vitro thrombus formation of platelets that were adhering to a collagen-immobilized plate, when thrombocytopenia-imitation blood was passed over the plate. Based on the flow cytometric analyses of PAC-1 binding and P-selectin expression, the H12-PEG-vesicles were shown not to cause platelet activation. Furthermore, the H12-PEG-vesicles dose-dependently shortened the tail bleeding time of thrombocytopenic rats. It was confirmed that the H12-PEG-vesicles had a hemostatic effect and may be a suitable candidate for an alternative to human platelet concentrates transfused into thrombocytopenic patients.",
author = "Yosuke Okamura and Ippei Maekawa and Yuji Teramura and Hitomi Maruyama and Makoto Handa and Yasuo Ikeda and Shinji Takeoka",
year = "2005",
month = "11",
doi = "10.1021/bc050178g",
language = "English",
volume = "16",
pages = "1589--1596",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Hemostatic effects of phospholipid vesicles carrying fibrinogen γ chain dodecapeptide in vitro and in vivo

AU - Okamura, Yosuke

AU - Maekawa, Ippei

AU - Teramura, Yuji

AU - Maruyama, Hitomi

AU - Handa, Makoto

AU - Ikeda, Yasuo

AU - Takeoka, Shinji

PY - 2005/11

Y1 - 2005/11

N2 - We studied prototypes of platelet substitutes that bear on their surface a dodecapeptide, HHLG-GAKQAGDV (H12). The peptide is a fibrinogen γ chain carboxy-terminal sequence (γ400-411) and recognizes specifically the active form of glycoprotein (GP) IIb/IIIa on the surface of activated platelets. We conjugated H12 to the end of poly(ethylene glycol) chains on the surface of a phospholipid vesicle with an average diameter of 220 nm to prepare H12-PEG-vesicles. The half-life of the H12-PEG-vesicles was significantly prolonged by PEG modification, and the ability of H12 on the surface of the vesicle to recognize GPIIb/IIIa was maintained even though the surface was modified with PEG chains. The H12-PEG-veiscles enhanced the in vitro thrombus formation of platelets that were adhering to a collagen-immobilized plate, when thrombocytopenia-imitation blood was passed over the plate. Based on the flow cytometric analyses of PAC-1 binding and P-selectin expression, the H12-PEG-vesicles were shown not to cause platelet activation. Furthermore, the H12-PEG-vesicles dose-dependently shortened the tail bleeding time of thrombocytopenic rats. It was confirmed that the H12-PEG-vesicles had a hemostatic effect and may be a suitable candidate for an alternative to human platelet concentrates transfused into thrombocytopenic patients.

AB - We studied prototypes of platelet substitutes that bear on their surface a dodecapeptide, HHLG-GAKQAGDV (H12). The peptide is a fibrinogen γ chain carboxy-terminal sequence (γ400-411) and recognizes specifically the active form of glycoprotein (GP) IIb/IIIa on the surface of activated platelets. We conjugated H12 to the end of poly(ethylene glycol) chains on the surface of a phospholipid vesicle with an average diameter of 220 nm to prepare H12-PEG-vesicles. The half-life of the H12-PEG-vesicles was significantly prolonged by PEG modification, and the ability of H12 on the surface of the vesicle to recognize GPIIb/IIIa was maintained even though the surface was modified with PEG chains. The H12-PEG-veiscles enhanced the in vitro thrombus formation of platelets that were adhering to a collagen-immobilized plate, when thrombocytopenia-imitation blood was passed over the plate. Based on the flow cytometric analyses of PAC-1 binding and P-selectin expression, the H12-PEG-vesicles were shown not to cause platelet activation. Furthermore, the H12-PEG-vesicles dose-dependently shortened the tail bleeding time of thrombocytopenic rats. It was confirmed that the H12-PEG-vesicles had a hemostatic effect and may be a suitable candidate for an alternative to human platelet concentrates transfused into thrombocytopenic patients.

UR - http://www.scopus.com/inward/record.url?scp=27944467898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944467898&partnerID=8YFLogxK

U2 - 10.1021/bc050178g

DO - 10.1021/bc050178g

M3 - Article

C2 - 16287259

AN - SCOPUS:27944467898

VL - 16

SP - 1589

EP - 1596

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 6

ER -